Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know.
Incyte beat analysts’ revenue expectations by 5.5% last quarter, reporting revenues of $1.22 billion, up 16.5% year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.
Is Incyte a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Incyte’s revenue to grow 10.6% year on year to $1.26 billion, slowing from the 23.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.64 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Incyte has missed Wall Street’s revenue estimates twice over the last two years.
With Incyte being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, there has been positive investor sentiment in the segment, with share prices up 7.6% on average over the last month. Incyte is up 9.4% during the same time and is heading into earnings with an average analyst price target of $85.81 (compared to the current share price of $91.76).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.